{"id":3039,"date":"2018-10-11T12:34:57","date_gmt":"2018-10-11T16:34:57","guid":{"rendered":"https:\/\/www.med.unc.edu\/genetherapy\/?post_type=directory&p=3039"},"modified":"2020-09-09T14:16:35","modified_gmt":"2020-09-09T18:16:35","slug":"thomas-mccown","status":"publish","type":"directory","link":"https:\/\/www.med.unc.edu\/genetherapy\/directory\/thomas-mccown\/","title":{"rendered":"Thomas McCown"},"content":{"rendered":"
Dr. McCown\u2019s overall research entails the development\u00a0of viral vector gene therapy for the treatment of neurological\u00a0disorders. With a primary focus upon intractable\u00a0temporal lobe epilepsy, Dr. McCown continues to refine\u00a0the use of site directed gene therapy, as well as advance\u00a0the potential of an intravenous AAV gene therapy. In\u00a0addition, Dr. McCown has employed AAV capsid DNA\u00a0shuffling and directed evolution in order to discover\u00a0novel AAV vectors that exhibit unique, therapy related\u00a0properties. These studies have resulted in the discovery of\u00a0chimeric AAV vectors that upon intravenous administration,\u00a0can selectively cross the seizure compromised bloodbrain\u00a0barrier, as well as novel vectors that exhibit unique\u00a0cell specific tropism in the CNS.<\/p>\n","protected":false},"excerpt":{"rendered":"
Research Interests Dr. McCown\u2019s overall research entails the development\u00a0of viral vector gene therapy for the treatment of neurological\u00a0disorders. With a primary focus upon intractable\u00a0temporal lobe epilepsy, Dr. McCown continues to refine\u00a0the use of site directed gene therapy, as well as advance\u00a0the potential of an intravenous AAV gene therapy. In\u00a0addition, Dr. McCown has employed AAV capsid … Read more<\/a><\/p>\n","protected":false},"featured_media":2422,"template":"","meta":{"_acf_changed":false,"_links_to":"","_links_to_target":""},"class_list":["post-3039","directory","type-directory","status-publish","has-post-thumbnail","hentry","odd"],"acf":[],"yoast_head":"\n